Home > Boards > US Listed > Biotechs > BrainStorm Cell Therapeutics Inc. (BCLI)

NEWS RELEASE

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 113
Posts 24,648
Boards Moderated 6
Alias Born 02/07/04
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/27/2020 6:05:32 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 10/1/2020 4:53:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/25/2020 4:16:53 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/25/2020 4:15:36 PM
Brainstorm Announces Grant of a New Japanese Patent for NurOwn® PR Newswire (US) - 9/16/2020 7:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/10/2020 4:08:28 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/3/2020 4:06:53 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 8/10/2020 6:07:14 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/5/2020 7:01:27 AM
BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update PR Newswire (US) - 8/5/2020 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 5:11:22 PM
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update PR Newswire (US) - 7/27/2020 7:58:00 AM
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS GlobeNewswire Inc. - 7/23/2020 7:00:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:16:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:10:56 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/16/2020 5:05:43 PM
BrainStorm Hosting KOL Webinar to Discuss NurOwn® Phase 2 Alzheimer's Disease Program PR Newswire (US) - 7/8/2020 5:31:00 AM
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 3 Clinical Trial in ALS PR Newswire (US) - 7/2/2020 6:49:00 AM
BrainStorm to Showcase Alzheimer's Disease Clinical Program in KOL Webinar PR Newswire (US) - 7/1/2020 8:50:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/26/2020 5:02:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/26/2020 5:01:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/26/2020 5:01:04 PM
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for the Treatment of Alzheimer's Disease PR Newswire (US) - 6/24/2020 7:00:00 AM
BrainStorm Granted SME Status by the European Medicines Agency GlobeNewswire Inc. - 6/15/2020 9:00:10 AM
BrainStorm to Present at the Raymond James Human Health Innovations Conference PR Newswire (US) - 6/11/2020 7:28:00 AM
midastouch017   Sunday, 08/16/20 08:33:17 AM
Re: None
Post # of 2837 
NEWS RELEASE
For Immediate Release
2020HLTH0252-001525
Aug. 14, 2020 Ministry of Health
Expanded ALS drug coverage to support British Columbians
VICTORIA – As of Wednesday, Aug. 19, 2020, the Ministry of Health will provide coverage of edaravone, or Radicava, for patients living with amyotrophic lateral sclerosis (ALS, commonly called Lou Gehrig’s disease) upon conclusion of negotiations with its manufacturer.

In British Columbia, approximately 480 people have been diagnosed with ALS. ALS is a fatal neurodegenerative disease where patients typically become unable to move, speak, swallow and breathe as the condition progresses. In one clinical trial, edaravone has helped slow the worsening of this disease in a select ALS patient subpopulation.

Edaravone has been under pan-Canadian Pharmaceutical Alliance (pCPA) negotiation since September 2019. The negotiations between the manufacturer, Mitsubishi Tanabe Pharma Corporation, and the pCPA meet B.C.’s cost-related mandate.

“The offer from Mitsubishi Tanabe Pharma Corporation meets British Columbia’s criteria, which is great news for patients suffering from this deadly disease,” said Adrian Dix, Minister of Health. “B.C. will continue to support ALS patients through its expansion of coverage of life-changing drugs and research funding to improve the lives of British Columbians.”

It is expected that between 66 to 183 patients will benefit from the coverage in the first year. The list price of edaravone is around $120,000 per patient, per year.

https://archive.news.gov.bc.ca/releases/news_releases_2017-2021/2020HLTH0252-001525.htm

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences